Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience - Inserm - Institut national de la santé et de la recherche médicale
Article Dans Une Revue Pediatric Blood and Cancer Année : 2024

Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience

Rachid Abbas

Résumé

Abstract Background Previous studies have shown that neutrophil‐to‐lymphocyte (NLR) ratio at diagnosis and early lymphocytes recovery on doxorubicin‐based chemotherapy, may impact the outcome in patients with osteosarcoma (OST). This study aimed to evaluate the prognostic value of hemogram parameters in patients with OST treated with high‐dose methotrexate and etoposide/ifosfamide (M‐EI) chemotherapy. Materials and methods We retrospectively analyzed the prognostic value of various hemogram parameters at diagnosis and during therapy in a large consecutive cohort of patients with OST included in the French OS2006 trial and treated with M‐EI chemotherapy. Results A total of 164 patients were analyzed. The median age was 14.7 years (interquartile range [IQR]: 11.7–17). Median follow‐up was 5.6 years (IQR: 3.3–7.7 years). Three‐year event‐free survival (EFS) and overall survival (OS) were 71.5% (95% confidence interval [CI]: 64%–78%) and 86.4% (95% CI: 80%–91%), respectively. In univariate analysis, blood count parameters at diagnosis and early lymphocyte recovery at Day 14 were not found prognostic of survival outcomes. By contrast, an increase of NLR ratio at Day 1 of the first EI chemotherapy (NLR‐W4) was associated with reduced OS in univariate ( p = .0044) and multivariate analysis (hazards ratio [HR] = 1.3, 95% CI: 1.1–1.5; p = .002), although not with EFS. After adjustment on histological response and metastatic status, an increase of the ratio NLR‐W4 of 1 was associated with an increased risk of death of 30%. Conclusions We identified NLR‐W4 as a potential early biomarker for survival in patients with OST treated with M‐EI chemotherapy. Further studies are required to confirm the prognostic value of NLR and better identify immune mechanisms involved in disease surveillance.
Fichier principal
Vignette du fichier
2024_Cozic_Abbas_PediatrBloodCancer.pdf (537.24 Ko) Télécharger le fichier
Origine Publication financée par une institution
Licence

Dates et versions

inserm-04707228 , version 1 (24-09-2024)

Licence

Identifiants

Citer

Paul Bastard, Nathalie Cozic, Régis Brion, Nathalie Gaspar, Sophie Piperno-Neumann, et al.. Prognostic value of hemogram parameters in osteosarcoma: The French OS2006 experience. Pediatric Blood and Cancer, 2024, 71 (7), pp.e31029. ⟨10.1002/pbc.31029⟩. ⟨inserm-04707228⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More